Author: Singh, Devendra; Wasan, Himika; Reeta, K.H.
Title: Heme oxygenase-1 modulation: a potential therapeutic target for COVID-19 and associated complications Cord-id: ncmlgiad Document date: 2020_10_19
ID: ncmlgiad
Snippet: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to infect hundred thousands of people every day worldwide. Since it is a novel virus, research continues to update the possible therapeutic targets when new evidence regarding COVID-19 are gathered. This article presents an evidence-based hypothesis that activating the heme oxygenase-1 (HO-1) pathway is a potential target for COVID-19. Interferons (IFNs) have broad-spectrum antivi
Document: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to infect hundred thousands of people every day worldwide. Since it is a novel virus, research continues to update the possible therapeutic targets when new evidence regarding COVID-19 are gathered. This article presents an evidence-based hypothesis that activating the heme oxygenase-1 (HO-1) pathway is a potential target for COVID-19. Interferons (IFNs) have broad-spectrum antiviral activity including against SARS-CoV-2. Induction of HO-1 and increase in the heme catabolism end-product confer antiviral activity. IFN activation-results in inhibition of viral replication in various viral infections. COVID-19 induces inflammation as well as acute respiratory distress syndrome (ARDS), and coagulopathies are now known major causes of mortality. A protective role of HO-1 induction in inflammation, inflammation-induced coagulation, and ARDS has been reported. Based on an association of HO-1 promoter polymorphisms and disease severity, we propose an evaluation of the status of these polymorphisms in COVID-19 patients who become severely ill. If an association is established, it might be helpful in identifying patients at high risk. Hence, we hypothesize that HO-1 pathway activation could be a therapeutic strategy against COVID-19 and associated complications.
Search related documents:
Co phrase search for related documents- acute inflammation and lung injury cause: 1, 2, 3, 4
- acute inflammation and lung liver: 1, 2, 3, 4
- acute inflammation lung injury and lung injury cause: 1, 2
- acute lps induce lung injury and lung liver: 1
- acute lung injury and lung injury cause: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute lung injury and lung liver: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- adaptive immunity and lung liver: 1, 2, 3, 4
- adaptive immunity innate and lung liver: 1, 2, 3
- additional evidence and lung liver: 1
- adhesion molecule and lung liver: 1, 2
- lopinavir ritonavir and lung injury cause: 1, 2
- lopinavir ritonavir and lung liver: 1, 2
- lopinavir ritonavir combination and lung liver: 1
- lps induce and lung liver: 1, 2
- lps induce lung injury and lung liver: 1
Co phrase search for related documents, hyperlinks ordered by date